知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.031 秒)

    Characterization of IL-17F and IL-17R interactions
    2.
    发明申请
    Characterization of IL-17F and IL-17R interactions 失效
    IL-17F和IL-17R相互作用的表征

    公开(公告)号：US20060257930A1

    公开(公告)日：2006-11-16

    申请号：US11354609

    申请日：2006-02-14

    申请人： Jay Kolls ,  Florencia McAllister ,  Beatriz Carreno ,  Samuel Goldman

    发明人： Jay Kolls ,  Florencia McAllister ,  Beatriz Carreno ,  Samuel Goldman

    IPC分类号： G01N33/53

    CPC分类号： G01N33/6893 ,  A61K38/00 ,  A61K38/1793 ,  A61K45/06 ,  C12N15/1136 ,  C12N2310/11 ,  C12N2310/14 ,  G01N33/6869 ,  G01N2500/00 ,  G01N2800/12 ,  G01N2800/382 ,  A61K2300/00

    摘要： The invention is related to findings that IL-17F-mediated inflammation of airway passages may be mediated via signaling through IL-17R on the basolateral surface of human respiratory epithelial cells. Thus, the present invention provides isolated and purified IL-17F or IL-17R polynucleotides and polypeptides. The present invention also is directed to novel methods for screening test compounds capable of inhibiting, i.e., decreasing, limiting, blocking, or otherwise reducing, IL-17F bioactivity, and methods for diagnosing, prognosing, and monitoring the progress of, disorders related to IL-17F bioactivity, e.g., disorders related to the effects of IL-17F binding to IL-17R on airway inflammation, e.g., in patients with cystic fibrosis, including pulmonary exacerbations due to bacterial infections in same. The present invention is further directed to novel therapeutics and therapeutic targets and to methods for the intervention (treatment) and prevention of said disorders related to IL-17F bioactivity.

    摘要翻译： 本发明涉及IL-17F介导的气道通道炎症可以通过IL-17R通过人呼吸上皮细胞的基底外侧表面的信号转导来发现。 因此，本发明提供分离和纯化的IL-17F或IL-17R多核苷酸和多肽。 本发明还涉及用于筛选能够抑制，即减少，限制，阻断或以其他方式降低IL-17F生物活性的测试化合物的新方法，以及用于诊断，预后和监测与 IL-17F生物活性，例如与IL-17F结合IL-17R对气道炎症的影响相关的疾病，例如囊性纤维化患者，包括由于细菌感染引起的肺部恶化。 本发明进一步涉及新的治疗和治疗靶标以及干预（治疗）和预防所述与IL-17F生物活性相关的疾病的方法。

    Inhibition of T cell activation by butyrophilin 4 or B7-L1
    6.
    发明申请
    Inhibition of T cell activation by butyrophilin 4 or B7-L1 审中-公开
    抑制丁酸生物素4或B7-L1对T细胞的活化

    公开(公告)号：US20060233819A1

    公开(公告)日：2006-10-19

    申请号：US11477982

    申请日：2006-06-29

    申请人： Clive Wood ,  Andrew Long ,  Beatriz Carreno

    发明人： Clive Wood ,  Andrew Long ,  Beatriz Carreno

    IPC分类号： A61K39/00

    CPC分类号： C07K14/70532 ,  A61K38/00 ,  C07K14/70503 ,  C07K2319/00 ,  C07K2319/30 ,  G01N33/505

    摘要： The invention provides methods for modulating an immune response comprising contacting an immune cell with an agent that modulates BTF4 or B7-L1 mediated signaling. BTF4 or B7-L1 mediated signaling may either be increased, to thereby downregulate the immune response, or alternatively may be decreased, to upregulate the immune response. Modulation may be either activation or inhibition, and contacting may occur in vivo or in vitro. Performance of this method in vivo is also potentially therapeutic for an individual who may benefit from the upregulation or downregulation of an immune response. Such modulation to downregulate the immune response serves as a therapeutic e.g., for an individual who has received an organ transplant, or has a condition such as an allergy, or an autoimmune disorder. Alternatively, modulation to upregulate the immune response serves as a therapeutic for an individual, e.g., who has a condition such as an immunosuppressive disorder or a tumor. Methods for identifying an agent that modulates BTF4 signaling or B7-L1 signaling is also provided.

    摘要翻译： 本发明提供了调节免疫应答的方法，包括使免疫细胞与调节BTF4或B7-L1介导的信号传导的药剂接触。 可以增加BTF4或B7-L1介导的信号传导，从而下调免疫应答，或者可以减少上调免疫应答。 调节可以是活化或抑制，并且接触可以在体内或体外发生。 该方法在体内的表现对于可能受益于免疫反应的上调或下调的个体也是潜在的治疗剂。 用于下调免疫应答的这种调节用作治疗剂，例如对于已经接受器官移植或具有诸如过敏或自身免疫病症的病症的个体。 或者，用于上调免疫应答的调节用作个体的治疗剂，例如患有诸如免疫抑制障碍或肿瘤的病症的个体。 还提供了用于识别调节BTF4信令或B7-L1信令的试剂的方法。